• FK866 (APO866): NAMPT Inhibition and Selective Cell Death in

  2026-04-25

  Explore how FK866 (APO866), a potent NAMPT inhibitor, uniquely enables the dissection of NAD metabolism and caspase-independent cell death in acute myeloid leukemia (AML) research. This article presents in-depth protocol guidance, mechanistic analysis, and practical insights for advanced hematologic cancer research.

• Dihydroartemisinin: Antimalarial and mTOR Pathway Inhibitor

  2026-04-24

  Dihydroartemisinin is a potent bioactive compound derived from the Artemisia plant, widely recognized for its antimalarial and anti-inflammatory properties. It acts as an mTOR signaling pathway inhibitor and is supplied by APExBIO with >98% purity for research use. This article details its mechanism, evidence, and practical workflow integration.

• HRP Goat Anti-Rabbit IgG (H+L) Antibody: Protocol & QC Guide

  2026-04-24

  The HRP Goat Anti-Rabbit IgG (H+L) Antibody addresses the need for reliable secondary detection and signal amplification in immunoassays relying on rabbit primary antibodies. This reagent is optimized for ELISA, Western blot, immunohistochemistry, and immunocytochemistry, but is not intended for diagnostic or clinical applications. Use is limited to workflows where rabbit IgG is the primary target and HRP-based detection is compatible with sample type and instrumentation.

• M344 HDAC Inhibition Suppresses Tumor Growth in Neuroblastom

  2026-04-23

  This study demonstrates that the histone deacetylase inhibitor M344 effectively suppresses neuroblastoma tumor growth through increased histone acetylation, cell cycle arrest, and induction of apoptosis. Its superior cytostatic and cytotoxic activity relative to established HDAC inhibitors highlights therapeutic potential and informs future preclinical research.

• Hoechst 33342 Solution (1 mg/mL): A Benchmark Nuclear Stain

  2026-04-23

  Hoechst 33342 is a blue fluorescent DNA stain optimized for live and fixed cell nuclear staining. It offers high membrane permeability, minimal cytotoxicity, and is validated for both microscopy and flow cytometry applications. The 1 mg/mL solution from APExBIO ensures standardized performance in research workflows.

• Itaconic Acid-Mediated TBK1 Alkylation Limits Type I IFN Res

  2026-04-22

  Chai et al. (2025) uncover a direct metabolic-immune axis in which IRG1-derived itaconic acid alkylates TBK1, disrupting its dimerization and restraining excessive type I interferon (IFN-I) signaling. This mechanistic insight identifies new avenues for controlling hyperinflammation and highlights metabolic feedback as a regulator of innate immunity.

• Lipid Nanoparticle Delivery of ABE8e Enables COL7A1 Correcti

  2026-04-22

  This study demonstrates targeted correction of COL7A1 mutations in dystrophic epidermolysis bullosa (DEB) fibroblasts using adenine base editor ABE8e delivered via lipid nanoparticles (LNPs). The research highlights a non-viral, RNA-based genome editing approach with high efficiency and minimal off-target effects, informing future therapeutic strategies for inherited skin disorders.

• CTDNEP1-NEP1R1 Complex: Differential Roles in ER Lipid Regul

  2026-04-21

  This study elucidates how the regulatory subunit NEP1R1 differentially modulates CTDNEP1 stability and function in the endoplasmic reticulum (ER), impacting lipid synthesis and storage. The findings clarify mechanisms maintaining lipid homeostasis and offer new perspectives on ER membrane expansion versus lipid droplet biogenesis.

• Nimbolide-Mediated E3 Ligase Targeting for Protein Degradati

  2026-04-21

  Spradlin et al. uncover nimbolide’s covalent targeting of E3 ligase RNF114, revealing a new mechanism for selective protein degradation in cancer cells. Their chemoproteomic approach provides a blueprint for leveraging natural products to expand the toolkit for targeted protein degradation.

• Ferroptosis-Related lncRNA Signature Predicts Pancreatic Can

  2026-04-20

  This study introduces a rigorously validated prognostic signature based on nine ferroptosis-related long non-coding RNAs for pancreatic adenocarcinoma. The signature enhances survival prediction and reveals links between ferroptosis, immune infiltration, and therapy response, providing new biomarkers and targets for cancer biology research.

• Optimizing Cancer Cell Assays with M344: Scenario-Driven Ins

  2026-04-20

  This article offers scenario-based guidance for biomedical researchers and technicians optimizing cell viability, proliferation, and cytotoxicity workflows with M344 (SKU A4105). Grounded in recent peer-reviewed data and real laboratory challenges, it demonstrates how M344’s potent and selective HDAC inhibition supports reproducible results in oncology and HIV-1 latency research.

• Patient-Derived Gastric Cancer Assembloids Reveal Stromal Im

  2026-04-19

  This study introduces a novel assembloid model integrating matched tumor organoids and stromal cell subpopulations from gastric cancer patients. By recapitulating tumor microenvironment complexity, the model enables detailed investigation of drug responses, biomarker profiles, and resistance mechanisms, advancing preclinical and personalized research.

• M344: Precision Histone Deacetylase Inhibitor for Cancer Res

  2026-04-18

  M344, a potent and cell-permeable histone deacetylase inhibitor, enables highly tunable epigenetic modulation, supporting advanced workflows in cancer biology and HIV-1 latency research. This article distills actionable protocols, troubleshooting guidance, and cross-domain insights to maximize the compound’s translational impact.

• Gap26 Connexin 43 Mimetic Peptide: Protocols and Application

  2026-04-17

  Gap26, a selective connexin 43 mimetic peptide, empowers researchers to precisely modulate gap junction signaling in neurobiology and vascular smooth muscle studies. This article navigates from validated workflows to troubleshooting, leveraging cutting-edge findings to optimize experimental design.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-04-16

  Schwartz’s dissertation introduces a refined framework for assessing anti-cancer drug responses by disentangling proliferation arrest from cell death in vitro. This approach improves mechanistic insight and assay interpretability, supporting the rational development and evaluation of targeted therapies.

16152 records 1/1077 page Next 12345 下5页 Last page